Popular Filters
Trials With No Placebo
MEK Inhibitor
MEKTOVI for Pediatric Craniopharyngioma
This trial tests MEKTOVI, a pill that targets cancer growth proteins, in children and young adults with a recurring brain tumor called Adamantinomatous Craniopharyngioma. The drug works by blocking signals that make cancer cells grow.
IL-6 receptor antagonist
ACTEMRA for Pediatric Craniopharyngioma
This trial tests ACTEMRA, a drug that blocks a protein called IL-6, in children with a recurring brain tumor called ACP. The goal is to see if it can reduce tumor growth and improve their quality of life.
Monoclonal Antibodies
Tocilizumab for Craniopharyngioma
This trial tests if tocilizumab, an anti-inflammatory drug, can reach and affect brain tumors in patients with craniopharyngioma. If successful, patients will receive the drug regularly over several months to see if it helps control their tumors.
Kinase Inhibitor
Vemurafenib + Cobimetinib for Craniopharyngioma
This trial tests vemurafenib and cobimetinib to treat patients with a certain type of brain tumor. The drugs may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Frequently Asked Questions
Introduction to craniopharyngioma
What are the top hospitals conducting craniopharyngioma research?
When it comes to advancing research and treatment options for the rare brain tumor known as craniopharyngioma, several top hospitals across the United States are at the forefront of innovation. In Philadelphia, the Children's Hospital of Philadelphia leads the way with three active clinical trials focused on this condition. Since their first recorded trial in 2016, they have been dedicated to finding better solutions for patients. Similarly, Children's Hospital Colorado in Aurora has also made significant contributions with three ongoing craniopharyngioma trials and a total of four conducted trials since their initial study in 2019.
In Memphis, Tennessee, St. Jude Children's Research Hospital demonstrates its commitment to fighting against this challenging tumor type with three active clinical trials currently underway and an impressive history of seven completed studies since their pioneering trial back in 2009. Meanwhile, at Children's National Medical Center in Washington D.C., researchers are diligently working on two active craniopharyngioma trials while having previously conducted three trials since their first investigation began in 2014.
Lastly but certainly not least is Ann & Robert H. Lurie Children's Hospital of Chicago which recently entered into this field by initiating its very first recorded craniopharyngioma trial just last year (2022). They may be newer players but already hold promise with two ongoing clinical tests focusing solely on craniopharygnomas out there.
These esteemed institutions represent a collective effort towards understanding and treating craniopharyngiomas more effectively. Through these dedicated medical teams' unwavering commitment to research and collaboration among experts nationwide, they offer hope not only for those affected by this rare brain tumor but also for advancements that can potentially impact other areas of neurology as well.
Which are the best cities for craniopharyngioma clinical trials?
When it comes to craniopharyngioma clinical trials, several cities are at the forefront of research and innovation. Grand Rapids in Michigan, Boston in Massachusetts, Houston in Texas, Minneapolis in Minnesota, and Philadelphia in Pennsylvania offer promising opportunities for individuals seeking participation. These cities have active trials studying various treatments such as Quality-of-Life Assessment, Guided Therapy, Binimetinib Oral Tablet [Mektovi], Tocilizumab, and DAY101. Through these ongoing studies, researchers aim to improve outcomes and quality of life for those affected by craniopharyngioma.
Which are the top treatments for craniopharyngioma being explored in clinical trials?
Craniopharyngioma, a rare brain tumor, is the focus of ongoing clinical trials exploring potential treatment options. Tocilizumab emerges as a top contender with two active trials and two all-time craniopharyngioma trials since its introduction in 2019. Another promising candidate is DAY101, currently being evaluated in one active trial for craniopharyngioma after its listing in 2022. Additionally, binimetinib oral tablet [Mektovi] shows promise with one active trial dedicated to this specific tumor type since it debuted on the scene in 2023. Lastly, quality-of-life assessment studies are also underway to ensure holistic care for patients affected by craniopharyngioma.
What are the most recent clinical trials for craniopharyngioma?
Recent clinical trials offer promising advancements in the treatment of craniopharyngioma, a rare type of brain tumor. One noteworthy trial focuses on binimetinib oral tablets (Mektovi), which is currently in Phase 2. This medication shows potential for improving outcomes and addressing the unique challenges associated with craniopharyngioma. Another study explores the efficacy of tocilizumab, also in Phase 2, as a targeted therapy option. Additionally, DAY101 has shown promise for treating this condition and is currently being investigated in Phase 2 trials. These ongoing efforts signify progress towards better understanding and managing craniopharyngioma to improve patients' quality of life.
What craniopharyngioma clinical trials were recently completed?
Recently completed clinical trials have provided valuable insights into the treatment of craniopharyngioma, a rare type of brain tumor. Notably, a trial investigating the efficacy and safety of [insert specific therapy] was successfully concluded in [month/year]. This study, sponsored by [sponsor's name], aimed to assess the potential benefits of this intervention for patients with craniopharyngioma. The completion of this trial represents an important step forward in our understanding and management of this challenging condition.